Abstract

BackgroundVirus-like particle (VLP) vaccines have recently emerged as a safe and effective alternative to conventional vaccine technologies. The strong immunogenic effects of VLPs can be harnessed for making vaccines against any pathogen by decorating VLPs with antigens from the pathogen. Producing the antigenic pathogen fragments and the VLP platform separately makes vaccine development rapid and convenient. Here we decorated the norovirus-like particle with two conserved influenza antigens and tested for the immunogenicity of the vaccine candidates in BALB/c mice.ResultsSpyTagged noro-VLP was expressed with high efficiency in insect cells and purified using industrially scalable methods. Like the native noro-VLP, SpyTagged noro-VLP is stable for months when refrigerated in a physiological buffer. The conserved influenza antigens were produced separately as SpyCatcher fusions in E. coli before covalent conjugation on the surface of noro-VLP. The noro-VLP had a high adjuvant effect, inducing high titers of antibody production against the antigens presented on its surface.ConclusionsThe modular noro-VLP vaccine platform presented here offers a rapid, convenient and safe method to present various soluble protein antigens to the immune system for vaccination and antibody production purposes.

Highlights

  • Virus-like particle (VLP) vaccines have recently emerged as a safe and effective alternative to conventional vaccine technologies

  • The best SpyTagnoro-VLP yields were obtained by infecting Hi5 insect cells with SpyTag-noro-VLP-expressing baculovirus at a multiplicity of infection (MOI) value of 1 and proceeding to the first crude purification step directly after collecting the expressed protein

  • Important for a vaccine platform, our studies demonstrate that the SpyTag-noro-VLP is stable and that it can be stored at normal refrigerator temperature for months

Read more

Summary

Introduction

Virus-like particle (VLP) vaccines have recently emerged as a safe and effective alternative to conventional vaccine technologies. Lampinen et al J Nanobiotechnol (2021) 19:25 They are virus-genome-free particles that are similar in size and shape to the respective viruses. This makes VLPs incapable of infection but still very effective in mounting immune responses [4]. Wherein the antigen and VLP are produced separately and conjugated together only after that, circumvents these problems Both native and decorated VLP vaccines, such as vaccines against human papilloma virus and malaria [Gardasil (MSD, Ireland), and Mosquirix H-W-2300 (GSK, UK), respectively], are already in clinical use, which demonstrates the commercial feasibility and medical potential of VLP technology. The modular VLP vaccine approach is not yet in clinical use, but with the research reported here, we aim to append to previous research on the subject and bring it closer to clinical testing

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.